Medical Billing Software for Podiatry Billing Companies

Short answer

Podiatry billing is harder than general practice billing for one structural reason: Medicare draws a sharp line between routine foot care and medically necessary foot care, and that line runs through every claim. Nail trimming is excluded. Nail trimming on a diabetic patient with documented loss of protective sensation and a class B vascular finding is covered. The same physical act, the same room, a different modifier and a documented clinical finding — that gap is where podiatry revenue is won or lost. Billing companies serving podiatry practices need software with a denial workflow that separates modifier errors from medical necessity denials from frequency limit hits, and a reporting layer that surfaces which pattern is driving write-offs across all clients at once. The AMA CPT code set and CMS NCD 70.2 are the governing references. The APMA publishes member guidance that tracks CMS policy changes closely.

Why podiatry billing has its own complexity

Most medical specialties have one or two coverage edge cases per payer. Podiatry has a coverage philosophy that applies at the code level across nearly every Medicare claim: unless the patient has a qualifying systemic condition with documented clinical findings in the chart, the service is presumed routine and denied before a human reviews it. This flows from Medicare Benefit Policy Manual, Chapter 15, Section 290, and it shapes how podiatry claims have to be built.

The practical consequence for a billing company is that claim denials in podiatry often look like clean claims that should have paid. The code is correct. The diagnosis is present. But the modifier is missing, or the class finding was documented in a prior visit note rather than the current encounter, or the physician managing the underlying condition did not send the six-month active care note the LCD requires. Those gaps do not trigger an edits engine. They trigger a denial after adjudication, which lands in the work queue rather than the scrubber.

A billing company managing five podiatry practices will see a higher proportion of medical necessity denials relative to technical rejections than in most other specialty mixes. The denial workflow — not just the scrubber — is where the operational leverage lives. The denial management workflow guide covers the queue structure and the patterns that separate recoverable denials from write-off candidates.

Podiatry also runs a wide revenue mix within a single practice: evaluation and management visits, nail and skin procedures, debridement, injections, surgical procedures with global periods, wound care, and DME. Each category has its own modifier rules, bundling restrictions, and frequency limits — a coding taxonomy that billing teams from general practice will find genuinely unfamiliar.

Medicare routine foot care: the Q7/Q8/Q9 modifier system

Medicare excludes routine foot care from Part B under its general exclusion for cosmetic, hygienic, and non-medically necessary services. Trimming toenails, filing calluses, and paring corns all fall there — even when a physician performs them. The coverage pathway for these procedures on Medicare patients runs through the class findings modifier system.

Q7 indicates one Class A finding: non-traumatic amputation of the foot or an integral skeletal portion — meaning the patient has already lost part of a foot to vascular disease or diabetes.

Q8 indicates two Class B findings. Class B includes absent dorsalis pedis pulse, absent posterior tibial pulse, or advanced trophic changes — which itself requires three discrete documented signs drawn from hair growth changes, nail thickening, skin texture changes, skin color changes, and skin temperature changes. Documenting "trophic changes present" without naming three specific signs does not satisfy the Class B definition.

Q9 indicates one Class B finding plus two Class C findings. Class C covers claudication, temperature changes in the foot, edema, paresthesias, and burning sensations. Q9 is the most commonly used modifier because the combination of one circulatory finding and two sensory symptoms matches the most frequently encountered clinical picture in a diabetic or vascular patient population.

All three modifiers attach to codes 11055, 11056, 11057 (paring and cutting of hyperkeratotic lesions), 11719, 11720, and 11721 (nail debridement), and G0127 (clipping of dystrophic nails). Without the modifier, any of these on a Medicare claim is denied as routine foot care. The modifier is a required claim element, not optional documentation shorthand.

A critical constraint: all class findings must be present in the foot being treated on that date of service — not from a different foot or a prior visit. Documentation must name the foot explicitly (left or right) for every finding asserted. A biller who pulls class findings from last month's note when the current note does not document them is building a claim that will not survive an audit.

Class findings and systemic conditions that justify coverage

Beyond the modifier, covered claims require a qualifying systemic condition diagnosis. The full list comes from CMS NCD 70.2 and IOM 100-02, Chapter 15, Section 290.

Metabolic and vascular conditions form the largest group in practice: diabetes mellitus, arteriosclerosis obliterans and other forms of occlusive peripheral arteriosclerosis, Buerger's disease, and chronic thrombophlebitis. Diabetes and chronic thrombophlebitis require documented active physician management — a treating physician must be actively managing the underlying condition, with a note within approximately six months to document that.

Peripheral neuropathies form a second group, covering those associated with nutritional deficiency (malnutrition, pellagra, alcoholism, malabsorption syndromes, pernicious anemia) and those associated with systemic conditions including diabetes, carcinoma, drug toxicity, multiple sclerosis, uremia, chronic renal disease, traumatic injury, leprosy, and neurosyphilis. Hereditary neuropathic conditions including hereditary sensory radicular neuropathy, Fabry's disease, and amyloid neuropathy also qualify.

Mycotic nails travel a separate coverage path. When 11720 or 11721 is billed for fungal nails, the primary diagnosis must be the dermatophytosis diagnosis, with a secondary diagnosis of the systemic condition or — if no systemic condition is present — a secondary diagnosis of secondary infection or pain. Mycotic nails as a standalone primary diagnosis, without a secondary qualifying code, are not covered.

CPT codes that drive podiatry revenue

Surgical codes in the 28000–28999 range cover foot and toe procedures from minor drainage through complex reconstructive osteotomies, most with 90-day global periods. Billing companies tracking podiatry surgical clients need to monitor when global periods open and close across each provider and flag post-op visits correctly. Cross-practice global period visibility requires the billing company to be the primary tenant of the system, not a guest in each practice's workspace.

Nail debridement versus nail removal: the denial pattern

The most persistently confused code pair in podiatry billing is 11720/11721 (debridement) versus 11730/11732 (avulsion/removal). Both services address thickened, painful, or infected nails, but they are different procedures with different documentation requirements and different coverage logic.

Debridement under 11720 or 11721 means reducing the thickness of an abnormal nail without removing the plate from the nail bed. Medicare covers it when the nail is mycotic or dystrophic and the appropriate systemic condition or qualifying diagnosis is present. Coding 11721 for six or more nails requires the note to document each nail by name with its individual condition.

Avulsion under 11730 means removing part or all of the nail plate from the nail bed — typically for an ingrown nail causing pain, infection, or granulation tissue. Avulsion does not use Q modifiers; the medical necessity pathway runs through the infection or pain condition. Documentation must describe the extent of involvement and whether the procedure was simple or combined with matrixectomy.

The denial pattern runs in both directions. A biller who codes 11720 for what was actually an avulsion may collect on the first pass if the Q modifier and systemic condition are present — until a post-payment audit finds that a nail plate was elevated from the bed and demands repayment. The reverse also happens: 11730 coded for what was actually conservative debridement, because the physician used "nail removal" in casual chart language. Payers scrutinize avulsion rates relative to debridement rates per provider, and a documentation mismatch on audit creates a repayment obligation.

The practice-level fix is documentation training. The billing-company fix is a denial review pattern that flags the code pair discrepancy across all clients simultaneously, which requires the denial workflow to support cross-practice querying by code and reason code combination.

Diabetic foot care and DME billing

The diabetic patient population drives a significant share of podiatry revenue and a disproportionate share of billing complexity. Two coverage pathways matter most: the LOPS pathway under NCD 70.2.1, and therapeutic footwear.

The LOPS pathway covers evaluation and care for patients with documented diabetic sensory neuropathy and loss of protective sensation. Under CMS NCD 70.2.1, Medicare covers this no more than once every six months. The diagnosis must be established before billing — a monofilament test result (absence of sensation at two or more of five tested sites using a 5.07 Semmes-Weinstein monofilament) must appear in the chart. G0245 covers the initial visit, G0246 covers follow-up, and G0247 covers routine foot care on the same date as either — it cannot stand alone.

The therapeutic footwear pathway covers diabetic shoes and inserts as DME. The standard annual benefit is one pair of depth-inlay shoes (A5500) and three pairs of inserts (A5512 or A5513). A KX modifier is required on each claim when all coverage criteria are met. If the practice is also the supplier billing the DME codes, it needs a DMEPOS enrollment with a separate NPI for that role.

The documentation failure rate for diabetic shoes is significant. CMS's 2024 fee-for-service supplemental data reported an improper payment rate of 47.1 percent for diabetic shoes, with insufficient documentation accounting for 85.5 percent of those improper payments. A pre-submission checklist verifying the prescribing note, the treatment plan, the diabetes diagnosis, the KX modifier, and the supplier enrollment is the standard mitigation for any billing company whose podiatry clients dispense footwear in volume.

How Medi handles podiatry billing-company workflows

Medi is built for billing companies managing multiple practices, not for a single practice doing its own billing. That distinction matters in podiatry because the operational problems — tracking modifier patterns across providers, catching debridement-versus-removal code confusion before it creates audit exposure, seeing which practices are trending toward frequency limit denials — are cross-practice problems that require a cross-practice view.

The denial workflow surfaces denials in a queue that can be worked across all client practices without switching contexts. A denial specialist can filter by reason code, code, or modifier across the entire book, which is how a billing company identifies that one practice's Q modifier documentation has slipped while the other four clients are clean.

ERA posting shows CARC and RARC codes translated to plain English, held lines separated from posted lines, and PLB segments as distinct entries. For a podiatry ERA that may mix surgical global period denials, routine foot care medical necessity denials, and straightforward copay applications, seeing the reason code on each line is how a poster makes the right posting decision without re-reading the remittance PDF.

The reporting layer aggregates across practices so an owner can see A/R aging, clean claim rate, and denial rate by practice in one view with drill-down to provider or code level. For more on the evaluation framework and how to compare platforms, see the billing company software evaluation guide and the billing company operations product overview.

What should a podiatry billing company verify in software?

The evaluation questions for podiatry are an extension of the general billing-company evaluation criteria, weighted toward denial and documentation workflows.

Review pricing and request a demo to evaluate whether the workflow depth fits your client mix.

When Medi is not the right fit

Medi does not include an EHR, scheduling, clinical documentation tools, or patient engagement modules. If your podiatry clients expect software that covers their clinical day — soap notes, templated exam forms, digital x-ray integration — a platform that bundles EHR with billing is a better fit.

Medi is not a DMEPOS inventory management platform. DME billing is supported on the claim and ERA side, but orthotic and footwear inventory management lives outside the product.

If your client mix is primarily practices doing their own billing in-house and needing a per-practice system, most cross-practice features in Medi do not apply and the pricing model may not fit a per-practice deployment relationship.

Frequently asked questions

What makes podiatry billing harder than general practice billing?

The Medicare routine foot care exclusion. Most services a podiatrist performs on a Medicare patient are presumed excluded until the claim includes a Q modifier, a documented class finding in the treating foot, and a qualifying systemic condition diagnosis. That three-part requirement does not appear in most other specialties, and it produces a category of medical necessity denials that look clean until adjudication. Billing teams from general practice often underestimate how much of a podiatry denial queue comes from this one coverage structure.

What are the Q7, Q8, and Q9 modifiers?

They communicate to Medicare which class of clinical findings is present in the foot being treated. Q7 signals one Class A finding (non-traumatic foot amputation). Q8 signals two Class B findings (absent pulses or advanced trophic changes with three documented signs). Q9 signals one Class B finding combined with two Class C findings (claudication, temperature changes, edema, paresthesias, or burning sensations). The modifiers attach to codes 11055–11057, 11719–11721, and G0127, and they are required claim elements — not optional — for those codes to be considered for Medicare payment.

What is the billing difference between nail debridement and nail removal?

Nail debridement under 11720 and 11721 reduces the thickness of a diseased nail without removing the plate from the nail bed; it requires a Q modifier for Medicare when the basis for coverage is a systemic condition. Nail removal under 11730 and 11732 avulses the nail plate from the nail bed for an ingrown or infected nail, and uses pain or infection as the medical necessity basis rather than Q modifiers. Billing one when the other was performed can surface as an overpayment demand on post-payment audit.

What is LOPS and how does it change podiatry billing?

LOPS is loss of protective sensation — a complication of diabetic peripheral neuropathy in which patients cannot feel injury to their feet. Under CMS NCD 70.2.1, Medicare covers foot examination and care for patients with documented LOPS no more than once every six months. HCPCS codes G0245 (initial), G0246 (follow-up), and G0247 (routine care same date as G0245 or G0246) apply. The diagnosis requires a documented monofilament test before billing begins. This pathway is separate from the Q modifier system and applies only to diabetic neuropathy.

How does diabetic shoe billing work, and why does it have a high denial rate?

The standard Medicare DME benefit covers one pair of depth-inlay shoes (A5500) and three pairs of inserts (A5512 or A5513) per calendar year for eligible diabetic patients. A KX modifier is required on each claim; if the practice is the supplier, it needs separate DMEPOS enrollment. CMS's 2024 data reported a 47.1 percent improper payment rate for diabetic shoes, with insufficient documentation driving 85.5 percent of those cases. A pre-submission checklist verifying the prescribing note, treatment plan, diabetes diagnosis, KX modifier, and supplier enrollment is the standard mitigation.

Can a podiatry practice bill an E&M visit on the same day as a nail or skin procedure?

Yes, when the evaluation is significant and separately identifiable from the procedure. Modifier 25 must attach to the E&M code to signal that it was distinct from the pre-procedure assessment bundled into the procedure fee. Without modifier 25, payers bundle the E&M into the procedure and deny the E&M line. A 99213 or 99215 billed on the same date as nail debridement is payable when the documentation supports the E&M level independently of the procedure note.

How often should a podiatry billing company audit Q modifier usage across its clients?

At minimum quarterly. The Q modifier system is a frequent RAC and MAC review target — the review looks for claims where the modifier was present but the chart documentation does not match the class finding asserted. A billing company that catches modifier-documentation mismatches internally can correct the root cause at the documentation training level before an audit request arrives. A quarterly pull of Q modifier claims matched against chart documentation is the practical audit rhythm for a podiatry-active book of business.